Additionally, our investigation of immune inhibitors, such as CD247, CD244, LAG3, TIGIT, and CTLA4, revealed their correlation with target genes, indicating their potential as therapeutic targets for CRC. The gene discussed is CD244; the disease is colorectal carcinoma.